ClinicalTrials.gg
CompletedNCT03559192Updated Apr 29, 2025Results posted

A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression

A Phase 2 interventional study of JNJ-67953964 and Placebo in Depressive Disorder, Major, sponsored by Janssen Research & Development, LLC. Completed at 53 sites in 6 countries. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
181
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Depressive Disorder, Major by Johnson & Johnson — 5 open to participants now, 5 under way, 5 of them phase 3. Depressive Disorder, Major · Johnson & Johnson.

Enrollment
29th of 52
181 · median 203
Started
2018
with 1 other
Phase 2
17 of 59
none open now
Registered
31st of 59
by date

Among the 59 studies in Depressive Disorder, Major by Johnson & Johnson, this one is the 29th largest by enrollment of the 52 interventional ones that give a count, is one of 2 that started in 2018, is one of 17 in phase 2, and was the 31st registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

5 of the 59 studies in Depressive Disorder, Major by Johnson & Johnson are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Depressive Disorder, Major by Johnson & Johnson, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of JNJ-67953964 compared to placebo when administered as adjunctive treatment in participants with Major Depressive Disorder (MDD) partially responsive to selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) treatment in terms of reduction of symptoms of depression, as assessed by the change from baseline on the Montgomery Asberg Depression Rating Scale (MADRS) in non-responders during the placebo lead-in period.

03

Conditions studied

  • Depressive Disorder, Major
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) between 18 and 35 kilogram per meter square (kg/m\^2) inclusive (BMI = weight/height\^2)
  • Participants must be medically stable based on clinical laboratory tests, medical history, vital signs, and 12-lead (ECG) performed at screening and baseline
  • Participants must have a primary 5th edition (DSM-5) diagnosis of Major Depressive Disorder (MDD)

    1. The current episode should be less than 18 months
    2. Participants should be currently treated with an SSRI or SNRI at an adequate dose and for at least 6 weeks but no more than 12 months
    3. Have a Montgomery-Asberg Depression Rating Scale (MADRS) total score greater than or equal to (>=) 25 at screening
  • A woman of must have a negative serum pregnancy test at screening and a negative urine pregnancy test before the first dose

Exclusion criteria

Exclusion Criteria:

  • History of documented gastric disease (including documented peptic ulcer disease, gastritis, upper gastrointestinal [GI] bleeding, esophagitis, or any GI precancerous condition), current clinically evident GI complaints
  • Chronic use of a proton pump inhibitors (PPIs). History of incidental use of PPIs is allowed but should have been stopped at least 4 weeks before screening. A history of chronic nonsteroidal anti-inflammatory drug (NSAID) or aspirin use. (Low dose aspirin for example in cardiovascular disease prevention is allowed)
  • Has a history of alcohol use disorder within the past year
  • Has failed (no more than 25 percent [%] response on Antidepressant Treatment History Questionnaire [ATRQ]) three or more antidepressant treatments including the current Selective serotonin reuptake inhibitor/ serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI) during the current depressive episode despite an adequate dose (per ATRQ) and duration (at least 6 weeks)
  • Has signs or symptoms of Cushing's Disease, Addison's Disease, primary amenorrhea, or other evidence of significant medical disorders of the hypothalamus pituitary adrenal (HPA) axis
  • Participant has received an drug (including investigational vaccines) or used an invasive investigational medical device within 3 months before the planned first dose of study drug or has participated in any interventional clinical studies on MDD in the previous 1 year or is currently enrolled in an interventional study
  • Has one or more of the following diagnoses:

    1. A primary DSM (5th edition) diagnosis of generalized anxiety disorder (GAD), panic disorder, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD). Participants with comorbid GAD, social anxiety disorder (SAD), or panic disorder for whom MDD is considered the primary diagnosis are not excluded
    2. A current diagnosis or diagnosis in the past 1 year of psychotic disorder, MDD with psychosis, anorexia nervosa or bulimia nervosa, chronic fatigue syndrome, bipolar disorder (BD), mental retardation, antisocial or borderline personality disorder, autism spectrum disorder
  • Has a current or recent history of suicidal ideation within the past 6 months, corresponding to a score of 4 (active suicidal ideation with some intent to act, without specific plan) or 5 (active suicidal ideation with specific plan and intent) for ideation on the Colombia suicide severity rating scale (C-SSRS), or a history of suicidal behavior within the past 1 year
  • Ongoing psychological treatments (example, Cognitive Behavior Therapy, Interpersonal Psychotherapy, Psychodynamic Psychotherapy, etcetera [etc.]), initiated within 1 month prior to the screening phase. A participant who has been receiving ongoing psychological treatment for a period of greater than 1 month from the screening visit is eligible, if the investigator deems the psychological treatment to be of stable duration and frequency
  • Participant has a history of substance use disorder according to criteria, except nicotine or caffeine, within 6 months before screening. Mild cases can be reviewed on a case by case basis. Participants who have completed a treatment for (alcohol) addiction more than 1 year prior to first dose administration, may be included if the risk of relapse is considered minimal, total duration of alcohol use disorder was less than a year, and no significant abnormalities are shown in clinical laboratory or other pre-dose safety assessments
  • Participant has used:

    1. Monoamine oxidase inhibitors (MAOIs) within 12 weeks before screening
    2. St. John's wort, ephedra, ginkgo, ginseng, or kava within 2 weeks before screening
    3. Antipsychotic drugs (D2-antagonists) within 2 weeks before screening. However, Seroquel (quetiapine) in a dose less than or equals to (\<=)100 milligram (mg) is allowed when used in a stable dose for at least 8 weeks prior to screening. Quetiapine treatment should be continued unchanged during the study
    4. Opioids within 2 weeks before screening
    5. Psychostimulants such as methylphenidate or dextroamphetamine within 2 weeks before screening
    6. Psychotropics with antidepressant effects such as atomoxetine or thyroid supplementation, in addition to their SSRI or SNRI treatment within 2 weeks before screening
  • Participant is unable to stop the following medication from the baseline visit (Visit 2) and throughout the study (tapering during screening period allowed): Any hypnotics including but not limited to: i. Benzodiazepines when used only as needed (PRN) are not allowed ii. Sedating antihistamines, including chronic use of diphenhydramine iii. Continuous use of zolpidem, zoplicon, eszopiclone and ramelteon. Note: Nonbenzodiazepines sleep aids (including: zolpidem, zaleplon, and eszopliclone) are allowed on an as needed (PRN) basis during the study but NOT within 24 hours before being in the clinic and not more than 2 nights in a row iv. S-adenosyl methionine (SAMe) v. Melatonin, agomelatine
  • Has received any prior treatment with electroconvulsive therapy, vagal nerve stimulation, or a deep brain stimulation device or treatment with ketamine or esketamine for MDD
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
181 participants (actual)

Study arms

  • Placebo comparator
    Lead-in Period: Placebo

    Participants will receive matching placebo for the entire duration of the lead-in period.

    Drug: Placebo

  • Experimental
    Treatment Period: JNJ-67953964 or Placebo

    Participants who respond or do not respond (based on reduction from lead-in baseline in MADRS) in the placebo lead-in period will receive either matching placebo or 10 (2\*5) milligram (mg) JNJ-67953964 capsules in a 1:1 ratio for 6 weeks.

    Drug: JNJ-67953964 · Drug: Placebo

  • Placebo comparator
    Withdrawal Period: Placebo

    Participants who complete the double-blind treatment period prior to the end of Week 11 will receive matching placebo for the remaining time of the treatment phase of the study.

    Drug: Placebo

Interventions

  • JNJ-67953964 10 mg will be administered as two 5-mg capsules orally once daily.

  • DrugPlacebo

    Matching placebo will be administered as 2 capsules orally once daily.

06

What researchers measure

Primary outcomes

  1. Change From Treatment Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Treatment Week 6 in Participants Who Were Non-Responders During Placebo Lead-in Period

    The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change from baseline indicates improvement.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

Secondary outcomes

  1. Change From Treatment Baseline in MADRS Total Score at Treatment Week 6

    The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change from baseline indicates improvement.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

  2. Number of Participants With Treatment-emergent Adverse Events (TEAEs) During DB Treatment Period

    An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product. TEAEs were AEs with onset during the treatment period that has worsened since baseline.

    Time frame: Up to Week 6

  3. Change From Treatment Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Treatment Week 6 (eITT Population)

    The SHAPS is a self-reported 14-item, instrument, developed for the assessment of hedonic capacity. Participants scored whether they experienced pleasure in performing a list of activities or experiences. Participants rated the answers as 1-4 where 1 indicates "Definitely agree", 2 indicates "Agree", 3 indicates "Disagree" and 4 indicates "Definitely disagree". The participant's item responses were summed to provide a total score ranging from 14 to 56. A higher total SHAPS score indicated higher levels of current anhedonia. Negative change from baseline indicated improvement.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

  4. Change From Treatment Baseline in SHAPS Total Score at Treatment Week 6 (fITT)

    The SHAPS is a self-reported 14-item, instrument, developed for the assessment of hedonic capacity. Participants scored whether they experienced pleasure in performing a list of activities or experiences. Participants rated the answers as 1-4 where 1 indicates "Definitely agree", 2 indicates "Agree", 3 indicates "Disagree" and 4 indicates "Definitely disagree". The participant's item responses were summed to provide a total score ranging from 14 to 56. A higher total SHAPS score indicated higher levels of current anhedonia. Negative change from baseline indicated improvement.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

  5. Change From Treatment Baseline in Clinical Global Impression - Severity (CGI-S) Score at Treatment Week 6 (eITT Population)

    CGI-S provides an overall clinician-determined summary measure of severity of participant's illness that considers all available information, including knowledge of participant's history, psychosocial circumstances, symptoms, behavior, and impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Participant is assessed on severity of mental illness at time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill participants. Negative change in score indicates improvement.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

  6. Change From Treatment Baseline in CGI-S Score at Treatment Week 6 (fITT Population)

    CGI-S provides an overall clinician-determined summary measure of severity of participants illness that considers all available information, including knowledge of participant's history, psychosocial circumstances, symptoms, behavior, and impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Participant is assessed on severity of mental illness at time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill participants. Negative change in score indicates improvement.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

  7. Change From Treatment Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score at Treatment Week 6 (eITT Population)

    The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item was rated by the participant according to a 5-point Likert scale. Participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") were combined into a single score by selecting the highest severity on either item. The total score was then created by summing the responses on the 15 items. The total score ranged from 0 to 60. The SMDDS uses a 7-day recall period and verbal rating scales. Higher score indicates more severe depressive symptomatology. Negative change from baseline indicates improvement.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

  8. Change From Treatment Baseline in SMDDS Total Score at Treatment Week 6 (fITT Population)

    The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item was rated by the participant according to a 5-point Likert scale. Participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") were combined into a single score by selecting the highest severity on either item. The total score was then created by summing the responses on the 15 items. The total score ranged from 0 to 60. The SMDDS uses a 7-day recall period and verbal rating scales. Higher score indicates more severe depressive symptomatology. Negative change from baseline indicates improvement.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

  9. Number of Participants With Self-Assessment of Treatment Experience (SATE) Questionnaire at Treatment Week 6 (eITT Population)

    SATE questionnaire is a 3-item self-reported scale designed to provide additional information regarding participant's subjective experience while taking treatment. This was internal Janssen questionnaire and questions were asked to participant weekly by the Q1.6-app. For rating overall depression: participant selected one option out of Improved, not changed or got worse; for depression improvement: participant selected one option out of slightly improved, much improved or very much improved; and for depression worsen: participant selected slightly worse, much worse or very much worse.

    Time frame: Treatment Week 6

  10. Number of Participants With SATE Questionnaire at Treatment Week 6 (fITT Population)

    SATE questionnaire is a 3-item self-reported scale designed to provide additional information regarding participant's subjective experience while taking treatment. This was internal Janssen questionnaire and questions were asked to participant weekly by the Q1.6-app. For rating overall depression: participant selected one option out of Improved, not changed or got worse; for depression improvement: participant selected one option out of slightly improved, much improved or very much improved; and for depression worsen: participant selected slightly worse, much worse or very much worse.

    Time frame: Treatment Week 6

  11. Change From Treatment Baseline in Hamilton Anxiety Scale 6 (HAM-A6) Total Score at Treatment Week 6 (eITT Population)

    HAM-A scale assesses severity of different anxiety-related symptoms with a score range of 0 to 52. Higher score indicated severity in anxiety symptoms. Each of the 14 items is rated by clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). HAM-A6 is a uni-dimensional, 6-item subscale derived from HAM-A. HAM-A6 comprises of five psychic anxiety symptoms: anxious mood, psychic tension, fears, intellectual disturbances, and anxious behaviour observed at the interview, as well as one somatic item, muscular tension. HAM-A6 subscale score ranges from 0 to 24, with higher scores indicating greater severity of core symptoms.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

  12. Change From Treatment Baseline in HAM-A6 Total Score at Treatment Week 6 (fITT)

    HAM-A scale assesses severity of different anxiety-related symptoms with a score range of 0 to 52. Higher score indicated severity in anxiety symptoms. Each of the 14 items is rated by clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). HAM-A6 is a uni-dimensional, 6-item subscale derived from HAM-A. HAM-A6 comprises of five psychic anxiety symptoms: anxious mood, psychic tension, fears, intellectual disturbances, and anxious behaviour observed at the interview, as well as one somatic item, muscular tension. HAM-A6 subscale score ranges from 0 to 24, with higher scores indicating greater severity of core symptoms.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

  13. Change From Treatment Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) Score at Treatment Week 6 (eITT Population)

    SIGH-A is a 14-item scale to measure severity of different anxiety-related symptoms in participants. Each of the 14 items is rated by the clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). The SIGH-A total score is calculated by summing the 14 item scores, and ranges from 0 to 56 where higher score indicates worsening.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

  14. Change From Treatment Baseline in SIGH-A Score at Treatment Week 6 (fITT Population)

    SIGH-A is a 14-item scale to measure severity of different anxiety-related symptoms in participants. Each of the 14 items is rated by the clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). The SIGH-A total score is calculated by summing the 14 item scores, and ranges from 0 to 56 where higher score indicates worsening.

    Time frame: Treatment Baseline up to Week 6 of DB-treatment period

  15. Maximum Observed Plasma Concentration (Cmax) of JNJ-67953964

    Cmax was defined as maximum observed plasma concentration of JNJ-67953964.

    Time frame: Week 1: Day 29, Week 3: Day 43, Week 6 (Day 64)

  16. Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC[0-24h]) of JNJ-67953964

    AUC(0-24h) was defined as the area under the plasma concentration-time curve from time of administration to 24 hours.

    Time frame: 0 to 24 hours Post dose on Week 1: Day 29, Week 3: Day 43, Week 6: Day 64

  17. Area Under Plasma Concentration-Time Curve at Steady State (AUCss) of JNJ-67953964

    AUCss was defined as the area under plasma concentration-time curve at Steady State (AUCss) of JNJ-67953964.

    Time frame: Week 1: Day 29, Week 3: Day 43, Week 6: Day 64

  18. Predose (Trough) Plasma Concentration (C0h) of JNJ-67953964

    C0h was defined as predose plasma Concentration of JNJ-67953964.

    Time frame: Predose on Week 1: Day 29, Week 3: Day 43, Week 6: Day 64

07

Results

Posted Jun 26, 2023

Participant flow

Lead-in Period (3 Weeks)
Participant flow — Lead-in Period (3 Weeks)
MilestoneLead in Period: PlaceboDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Started18100
Completed16900
Not completed1200
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject600
Withdrew: Adverse event500
DB Treatment(6 Wks) + Withdrawal(2 Wks)
Participant flow — DB Treatment(6 Wks) + Withdrawal(2 Wks)
MilestoneLead in Period: PlaceboDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Started08485
Placebo lead-in responders02223
Placebo lead-in non-responders06262
Completed db period and entered withdrawal08180
Completed08179
Not completed036
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject010
Withdrew: Lack of efficacy002
Withdrew: Adverse event011
Withdrew: Non-compliance with study drug001
Withdrew: Other011

Outcome measures

PrimaryChange From Treatment Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Treatment Week 6 in Participants Who Were Non-Responders During Placebo Lead-in Period

The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change from baseline indicates improvement.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Least squares mean · scores on a scale
Change From Treatment Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Treatment Week 6 in Participants Who Were Non-Responders During Placebo Lead-in Period
scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Treatment Week 6 in Participants Who Were Non-Responders During Placebo Lead-in Period-8.0 ± 0.92-10.1 ± 0.93
Statistical analysis
  • Double-blind Treatment + Withdrawal Period: Placebo vs Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) · Mixed Models Analysis · p = = 0.0443 · Least squares mean difference: -2.1
SecondaryChange From Treatment Baseline in MADRS Total Score at Treatment Week 6

The MADRS is a clinician-rated scale designed to measure depression severity and detects changes due to antidepressant treatment. The scale consists of 10 items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 60. Higher scores represent a more severe condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep appetite, concentration, lassitude, inability to feel (interest level), pessimistic thoughts, and suicidal thoughts. Negative change from baseline indicates improvement.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Least squares mean · scores on a scale
Change From Treatment Baseline in MADRS Total Score at Treatment Week 6
scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in MADRS Total Score at Treatment Week 6-6.5 ± 0.78-9.6 ± 0.79
Statistical analysis
  • Double-blind Treatment + Withdrawal Period: Placebo vs Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) · Mixed Models Analysis · p = 0.0017 · Least squares mean difference: -3.1
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) During DB Treatment Period

An AE can be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product. TEAEs were AEs with onset during the treatment period that has worsened since baseline.

Time frame:
Up to Week 6
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During DB Treatment Period
ParticipantsDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During DB Treatment Period3040
SecondaryChange From Treatment Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Treatment Week 6 (eITT Population)

The SHAPS is a self-reported 14-item, instrument, developed for the assessment of hedonic capacity. Participants scored whether they experienced pleasure in performing a list of activities or experiences. Participants rated the answers as 1-4 where 1 indicates "Definitely agree", 2 indicates "Agree", 3 indicates "Disagree" and 4 indicates "Definitely disagree". The participant's item responses were summed to provide a total score ranging from 14 to 56. A higher total SHAPS score indicated higher levels of current anhedonia. Negative change from baseline indicated improvement.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Least squares mean · scores on a scale
Change From Treatment Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Treatment Week 6 (eITT Population)
scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in Snaith-Hamilton Pleasure Scale (SHAPS) Total Score at Treatment Week 6 (eITT Population)-3.7 ± 0.64-4.4 ± 0.64
Statistical analysis
  • Double-blind Treatment + Withdrawal Period: Placebo vs Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) · Mixed Models Analysis · p = = 0.4188 · Least squares mean difference: -0.7
SecondaryChange From Treatment Baseline in SHAPS Total Score at Treatment Week 6 (fITT)

The SHAPS is a self-reported 14-item, instrument, developed for the assessment of hedonic capacity. Participants scored whether they experienced pleasure in performing a list of activities or experiences. Participants rated the answers as 1-4 where 1 indicates "Definitely agree", 2 indicates "Agree", 3 indicates "Disagree" and 4 indicates "Definitely disagree". The participant's item responses were summed to provide a total score ranging from 14 to 56. A higher total SHAPS score indicated higher levels of current anhedonia. Negative change from baseline indicated improvement.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Least squares mean · scores on a scale
Change From Treatment Baseline in SHAPS Total Score at Treatment Week 6 (fITT)
scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in SHAPS Total Score at Treatment Week 6 (fITT)-3.7 ± 0.55-4.5 ± 0.55
Statistical analysis
  • Double-blind Treatment + Withdrawal Period: Placebo vs Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg) · Mixed Models Analysis · p = 0.2503 · Least squares mean difference: -0.8
SecondaryChange From Treatment Baseline in Clinical Global Impression - Severity (CGI-S) Score at Treatment Week 6 (eITT Population)

CGI-S provides an overall clinician-determined summary measure of severity of participant's illness that considers all available information, including knowledge of participant's history, psychosocial circumstances, symptoms, behavior, and impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Participant is assessed on severity of mental illness at time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill participants. Negative change in score indicates improvement.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Mean · Scores on a scale
Change From Treatment Baseline in Clinical Global Impression - Severity (CGI-S) Score at Treatment Week 6 (eITT Population)
Scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in Clinical Global Impression - Severity (CGI-S) Score at Treatment Week 6 (eITT Population)-0.76 ± 0.858-0.92 ± 1.039
SecondaryChange From Treatment Baseline in CGI-S Score at Treatment Week 6 (fITT Population)

CGI-S provides an overall clinician-determined summary measure of severity of participants illness that considers all available information, including knowledge of participant's history, psychosocial circumstances, symptoms, behavior, and impact of symptoms on participant's ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Participant is assessed on severity of mental illness at time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill participants. Negative change in score indicates improvement.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Mean · Scores on a scale
Change From Treatment Baseline in CGI-S Score at Treatment Week 6 (fITT Population)
Scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in CGI-S Score at Treatment Week 6 (fITT Population)-0.67 ± 0.880-0.87 ± 1.005
SecondaryChange From Treatment Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score at Treatment Week 6 (eITT Population)

The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item was rated by the participant according to a 5-point Likert scale. Participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") were combined into a single score by selecting the highest severity on either item. The total score was then created by summing the responses on the 15 items. The total score ranged from 0 to 60. The SMDDS uses a 7-day recall period and verbal rating scales. Higher score indicates more severe depressive symptomatology. Negative change from baseline indicates improvement.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Mean · Scores on a scale
Change From Treatment Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score at Treatment Week 6 (eITT Population)
Scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in Symptoms of Major Depressive Disorder Scale (SMDDS) Total Score at Treatment Week 6 (eITT Population)-8.49 ± 9.567-8.03 ± 9.957
SecondaryChange From Treatment Baseline in SMDDS Total Score at Treatment Week 6 (fITT Population)

The SMDDS is a 16-item patient reported outcome (PRO) measure. Each item was rated by the participant according to a 5-point Likert scale. Participants respond to each question using a rating scale between 0 ("Not at all" or "Never") to 4 ("Extremely" or "Always"). Before summing the items to create a total score, item 11 ("how often did you have a poor appetite") and item 12 ("how often did you over eat") were combined into a single score by selecting the highest severity on either item. The total score was then created by summing the responses on the 15 items. The total score ranged from 0 to 60. The SMDDS uses a 7-day recall period and verbal rating scales. Higher score indicates more severe depressive symptomatology. Negative change from baseline indicates improvement.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Mean · Scores on a scale
Change From Treatment Baseline in SMDDS Total Score at Treatment Week 6 (fITT Population)
Scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in SMDDS Total Score at Treatment Week 6 (fITT Population)-6.91 ± 9.996-8.16 ± 9.470
SecondaryNumber of Participants With Self-Assessment of Treatment Experience (SATE) Questionnaire at Treatment Week 6 (eITT Population)

SATE questionnaire is a 3-item self-reported scale designed to provide additional information regarding participant's subjective experience while taking treatment. This was internal Janssen questionnaire and questions were asked to participant weekly by the Q1.6-app. For rating overall depression: participant selected one option out of Improved, not changed or got worse; for depression improvement: participant selected one option out of slightly improved, much improved or very much improved; and for depression worsen: participant selected slightly worse, much worse or very much worse.

Time frame:
Treatment Week 6
Reported as:
Count of participants · Participants
Number of Participants With Self-Assessment of Treatment Experience (SATE) Questionnaire at Treatment Week 6 (eITT Population)
ParticipantsDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Overall Depression (Got worse)10
Overall Depression (Not changed)129
Overall Depression (Improved)2721
Depression Worsened (Slightly worse)1—
Depression Worsened (Much worse)0—
Depression Worsened (Very much worse)0—
Depression Improvement (Slightly improved)1315
Depression Improvement (Much improved)116
Depression Improvement (Very Much Improved)30
SecondaryNumber of Participants With SATE Questionnaire at Treatment Week 6 (fITT Population)

SATE questionnaire is a 3-item self-reported scale designed to provide additional information regarding participant's subjective experience while taking treatment. This was internal Janssen questionnaire and questions were asked to participant weekly by the Q1.6-app. For rating overall depression: participant selected one option out of Improved, not changed or got worse; for depression improvement: participant selected one option out of slightly improved, much improved or very much improved; and for depression worsen: participant selected slightly worse, much worse or very much worse.

Time frame:
Treatment Week 6
Reported as:
Count of participants · Participants
Number of Participants With SATE Questionnaire at Treatment Week 6 (fITT Population)
ParticipantsDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Overall Depression (Got worse)10
Overall Depression (Not changed)1512
Overall Depression (Improved)3330
Depression Worsened (Slightly worse)1—
Depression Worsened (Much worse)0—
Depression Worsened (Very much worse)0—
Depression Improvement (Slightly improved)1820
Depression Improvement (Much improved)129
Depression Improvement (Very Much Improved)31
SecondaryChange From Treatment Baseline in Hamilton Anxiety Scale 6 (HAM-A6) Total Score at Treatment Week 6 (eITT Population)

HAM-A scale assesses severity of different anxiety-related symptoms with a score range of 0 to 52. Higher score indicated severity in anxiety symptoms. Each of the 14 items is rated by clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). HAM-A6 is a uni-dimensional, 6-item subscale derived from HAM-A. HAM-A6 comprises of five psychic anxiety symptoms: anxious mood, psychic tension, fears, intellectual disturbances, and anxious behaviour observed at the interview, as well as one somatic item, muscular tension. HAM-A6 subscale score ranges from 0 to 24, with higher scores indicating greater severity of core symptoms.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Mean · scores on a scale
Change From Treatment Baseline in Hamilton Anxiety Scale 6 (HAM-A6) Total Score at Treatment Week 6 (eITT Population)
scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in Hamilton Anxiety Scale 6 (HAM-A6) Total Score at Treatment Week 6 (eITT Population)-2.19 ± 2.837-2.73 ± 2.651
SecondaryChange From Treatment Baseline in HAM-A6 Total Score at Treatment Week 6 (fITT)

HAM-A scale assesses severity of different anxiety-related symptoms with a score range of 0 to 52. Higher score indicated severity in anxiety symptoms. Each of the 14 items is rated by clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). HAM-A6 is a uni-dimensional, 6-item subscale derived from HAM-A. HAM-A6 comprises of five psychic anxiety symptoms: anxious mood, psychic tension, fears, intellectual disturbances, and anxious behaviour observed at the interview, as well as one somatic item, muscular tension. HAM-A6 subscale score ranges from 0 to 24, with higher scores indicating greater severity of core symptoms.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Mean · scores on a scale
Change From Treatment Baseline in HAM-A6 Total Score at Treatment Week 6 (fITT)
scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in HAM-A6 Total Score at Treatment Week 6 (fITT)-1.67 ± 2.842-2.68 ± 2.562
SecondaryChange From Treatment Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) Score at Treatment Week 6 (eITT Population)

SIGH-A is a 14-item scale to measure severity of different anxiety-related symptoms in participants. Each of the 14 items is rated by the clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). The SIGH-A total score is calculated by summing the 14 item scores, and ranges from 0 to 56 where higher score indicates worsening.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Mean · scores on a scale
Change From Treatment Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) Score at Treatment Week 6 (eITT Population)
scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in Structured Interview Guide for the Hamilton Anxiety Rating Scale (SIGH-A) Score at Treatment Week 6 (eITT Population)-5.37 ± 6.549-5.85 ± 5.369
SecondaryChange From Treatment Baseline in SIGH-A Score at Treatment Week 6 (fITT Population)

SIGH-A is a 14-item scale to measure severity of different anxiety-related symptoms in participants. Each of the 14 items is rated by the clinician on a 5-point scale ranging from 0 (not present) to 4 (maximum degree). The SIGH-A total score is calculated by summing the 14 item scores, and ranges from 0 to 56 where higher score indicates worsening.

Time frame:
Treatment Baseline up to Week 6 of DB-treatment period
Reported as:
Mean · scores on a scale
Change From Treatment Baseline in SIGH-A Score at Treatment Week 6 (fITT Population)
scores on a scaleDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Change From Treatment Baseline in SIGH-A Score at Treatment Week 6 (fITT Population)-4.35 ± 6.193-5.47 ± 4.988
SecondaryMaximum Observed Plasma Concentration (Cmax) of JNJ-67953964

Cmax was defined as maximum observed plasma concentration of JNJ-67953964.

Time frame:
Week 1: Day 29, Week 3: Day 43, Week 6 (Day 64)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of JNJ-67953964
nanograms per milliliter (ng/mL)Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Week 1 (Day 29)32.7 ± 10.9
Week 3 (Day 43)33.5 ± 11.1
Week 6 (Day 64)34.3 ± 11.1
SecondaryArea Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC[0-24h]) of JNJ-67953964

AUC(0-24h) was defined as the area under the plasma concentration-time curve from time of administration to 24 hours.

Time frame:
0 to 24 hours Post dose on Week 1: Day 29, Week 3: Day 43, Week 6: Day 64
Reported as:
Mean · nanograms*hour per milliliter (ng*h/mL)
Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC[0-24h]) of JNJ-67953964
nanograms*hour per milliliter (ng*h/mL)Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Week 1 (Day 29)361 ± 156
Week 3 (Day 43)377 ± 164
Week 6 (Day 64)378 ± 163
SecondaryArea Under Plasma Concentration-Time Curve at Steady State (AUCss) of JNJ-67953964

AUCss was defined as the area under plasma concentration-time curve at Steady State (AUCss) of JNJ-67953964.

Time frame:
Week 1: Day 29, Week 3: Day 43, Week 6: Day 64
Reported as:
Mean · ng*h/mL
Area Under Plasma Concentration-Time Curve at Steady State (AUCss) of JNJ-67953964
ng*h/mLDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Week 1 (Day 29)380 ± 151
Week 3 (Day 43)380 ± 151
Week 6 (Day 64)379 ± 153
SecondaryPredose (Trough) Plasma Concentration (C0h) of JNJ-67953964

C0h was defined as predose plasma Concentration of JNJ-67953964.

Time frame:
Predose on Week 1: Day 29, Week 3: Day 43, Week 6: Day 64
Reported as:
Mean · nanograms per milliliter (ng/ml)
Predose (Trough) Plasma Concentration (C0h) of JNJ-67953964
nanograms per milliliter (ng/ml)Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Week 1 (Day 29)8.62 ± 4.27
Week 3 (Day 43)9.40 ± 4.69
Week 6 (Day 64)9.48 ± 4.83

Adverse events

Collected over Up to Week 11. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lead in Period: Placebo0/169 (0%)0/169 (0%)21/169 (12.4%)
Double-blind Treatment + Withdrawal Period: Placebo0/84 (0%)1/84 (1.2%)10/84 (11.9%)
Double-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)0/85 (0%)0/85 (0%)23/85 (27.1%)
Most frequent serious events
Most frequent serious events
EventLead in Period: PlaceboDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
Cholecystitis AcuteHepatobiliary disorders0/1691/840/85
Most frequent other events
Most frequent other events
EventLead in Period: PlaceboDouble-blind Treatment + Withdrawal Period: PlaceboDouble-blind Treatment + Withdrawal Period: JNJ-67953964 10 Milligrams (mg)
HeadacheNervous system disorders11/1697/8410/85
DiarrhoeaGastrointestinal disorders6/1692/847/85
NasopharyngitisInfections and infestations6/1693/846/85
PruritusSkin and subcutaneous tissue disorders1/1690/845/85

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lead in Period: Placebo
Mean42.5 ± 12.91
Age, Customized
Age, Customized(Participants)Lead in Period: Placebo
Adults (18-64 years)181
Sex: Female, Male
Sex: Female, Male(Participants)Lead in Period: Placebo
Female131
Male50
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lead in Period: Placebo
Hispanic or Latino25
Not Hispanic or Latino156
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lead in Period: Placebo
American Indian or Alaska Native1
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American8
White167
More than one race0
Unknown or Not Reported0
08

Study locations

53 sites
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Preferred Research Partners
    Little Rock, Arkansas 72211, United States
  • Behavioral Research Specialists LLC
    Glendale, California 91206, United States
  • NRC Research Institute
    Orange, California 92868, United States
  • Artemis Institute for Clinical Research
    Riverside, California 92503, United States
  • Artemis Institute for Clinical Research
    San Marcos, California 92078, United States
  • Pacific Clinical Research Medical Group
    Upland, California 91786, United States
  • Galiz Research
    Miami Springs, Florida 33166, United States
  • Innova Clinical Trials
    Miami, Florida 33133, United States
  • APG Research LLC
    Orlando, Florida 32803, United States
  • Olympian Clinical Research
    Tampa, Florida 33614, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Atlanta Behavioral Research, LLC
    Atlanta, Georgia 30338, United States
  • Chicago Research Center
    Chicago, Illinois 60634, United States
  • Psychiatric Medicine Associates LLC
    Skokie, Illinois 60076, United States
  • Lake Charles Clinical Trials
    Lake Charles, Louisiana 70629, United States
  • Princeton Medical Institute
    Princeton, New Jersey 08540, United States
  • Integrative Clinical Trials LLC
    Brooklyn, New York 11229, United States
  • Richmond Behavioural Associates
    Staten Island, New York 10312, United States
  • Clinical Trials of America
    Hickory, North Carolina 28601, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • IPS Research Company
    Oklahoma City, Oklahoma 73106, United States
  • Paradigm Research Professionals, LLC
    Oklahoma City, Oklahoma 73118, United States
  • Lehigh Center for Clinical Research
    Allentown, Pennsylvania 18104, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Clinical NeuroScience Solutions Inc
    Memphis, Tennessee 38119, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • Emovis GmbH
    Berlin, 10629, Germany
  • Somni Bene GmbH
    Schwerin, 19053, Germany
  • ARENSIA
    Chisinau, MD2025, Moldova, Republic of
  • Sverdlovsk Regional Clinical Psychiatric Hospital
    Ekaterinburg, Russian Federation
  • Clinical Psychiatric Hospital #3 Named After V.A. Gilyarovsky
    Moscow, 107076, Russian Federation
  • Orenburg Regional Clinical Psychiatric Hospital #1
    Orenburg, Russian Federation
  • Medical and Rehabilitation Research Center Phoenix
    Rostov-on-Don, 344002, Russian Federation
  • Engels psychiatric hospital
    Saratov Region, 413124, Russian Federation
  • SHI 'Saratov City Clinical Hospital 2 n.a V.I. Razumovsky
    Saratov, 410028, Russian Federation
  • Saratov Regional Psychiatric hospital named after St. Sofia
    Saratov, 410060, Russian Federation
  • City Psychiatric hospital 7 named after I.P.Pavlov
    St-Petersburg, 199034, Russian Federation
  • Psychoneurological dispensary 1
    St-Petersburg, 199178, Russian Federation
  • St-Petersburg Bekhterev Psychoneurological Research Institute
    St. Petersburg, 192019, Russian Federation
  • Research Institute of Mental Health
    Tomsk, 634014, Russian Federation
  • MNCE of Kyiv RC Regional Psychiatric and Narcological Medical Association
    Glevakha, 8630, Ukraine
  • Mnpe of Kharkiv Regional Council 'Regional Clinical Psychiatric Hospital #3'
    Kharkiv, 61068, Ukraine
  • CNPE'Kherson Regional Institution of Mental Care'of Kherson Regional Council
    Kherson, 73488, Ukraine
  • Cnce 'Kyiv City Psychoneurological Hospital #2' of Executive Body of Kyiv City Council (Kcsa)
    Kyiv, 2660, Ukraine
  • Mnpe 'Regional Clinical Psychiatric Hospital of Kirovohrad Regional Council'
    Nove, 25491, Ukraine
  • CNCE 'Cherkasy Regional Psychiatric Hospital of Cherkasy Regional Council'
    Smila, 20708, Ukraine
  • MAC Clinical Research
    Barnsley, S75 3DL, United Kingdom
  • MAC Clinical Research
    Blackpool, FY2 0JH, United Kingdom
  • MAC Clinical Research
    Liverpool, L34 1BH, United Kingdom
  • Hammersmith Medicines Research Ltd
    London, NW10 7EW, United Kingdom
  • MAC Clinical Research
    Manchester, M139NQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in May 2020, 21 months.

Results were first posted in Jun 2023, 3 years 1 month after primary completion. A results delay was requested in May 2021.

Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 21 months is above that.

Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2018
First posted
Jun 18, 2018
StartActual
Jul 16, 2018
Primary completionActual
May 6, 2020
CompletionActual
May 6, 2020
Results delay requested
May 3, 2021
Results first posted
Jun 26, 2023
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03559192
Responsible party
Sponsor
First posted
Jun 18, 2018
Start date
Jul 16, 2018
Primary completion
May 6, 2020
Completion
May 6, 2020
Results posted
Jun 26, 2023
Last update
Apr 29, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aticaprant

Start the discussion